268 related articles for article (PubMed ID: 11042654)
1. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Jantunen E; Mahlamäki E; Nousiainen T
Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654
[TBL] [Abstract][Full Text] [Related]
2. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution.
Magagnoli M; Castagna L; Balzarotti M; Sarina B; Timofeeva I; Bertuzzi A; Compasso S; Nozza A; Siracusano L; Santoro A
Am J Hematol; 2003 Aug; 73(4):267-72. PubMed ID: 12879431
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M
Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
[TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Weaver CH; Schwartzberg L; Rhinehart S; West J; Zhen B; West WH; Buckner CD
Bone Marrow Transplant; 1998 Feb; 21(4):383-9. PubMed ID: 9509973
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
[TBL] [Abstract][Full Text] [Related]
8. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
Moreau P; Milpied N; Voillat L; Colombat P; Mahé B; Rapp MJ; Moreau A; Dupas B; Bulabois CE; Juge-Morineau N; Harousseau JL
Bone Marrow Transplant; 1998 Jun; 21(12):1193-6. PubMed ID: 9674850
[TBL] [Abstract][Full Text] [Related]
11. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
12. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[TBL] [Abstract][Full Text] [Related]
13. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
[TBL] [Abstract][Full Text] [Related]
15. [High-dose therapy and peripheral blood stem cell transplantation for patients with aggressive non-Hodgkin's lymphoma remaining in initial remission: results of a feasibility study].
Kitajima H; Nasu K; Tsudo M; Fujimoto M; Hayashi K; Ohno H; Konaka Y; Katsurada T; Arima N; Doi S; Moriguchi T; Fukuhara S
Rinsho Ketsueki; 2001 Mar; 42(3):191-8. PubMed ID: 11345781
[TBL] [Abstract][Full Text] [Related]
16. [A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate-grade non-Hodgkin's lymphoma. Japan Blood Cell Transplantation Study Group].
Chou T; Ishiguro T; Imajo K; Kawano F; Gondo H; Kasai M; Masuda M; Koike M; Shimazaki C; Hara M; Shinagawa K; Ogawa M; Takaku F; Harada M
Rinsho Ketsueki; 1999 Oct; 40(10):1058-67. PubMed ID: 10565222
[TBL] [Abstract][Full Text] [Related]
17. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
[TBL] [Abstract][Full Text] [Related]
18. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
Seropian S; Nadkarni R; Jillella AP; Salloum E; Burtness B; Hu GL; Zelterman D; Cooper DL
Bone Marrow Transplant; 1999 Mar; 23(6):599-605. PubMed ID: 10217191
[TBL] [Abstract][Full Text] [Related]
19. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
[TBL] [Abstract][Full Text] [Related]
20. Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
Vela-Ojeda J; Tripp-Villanueva F; Montiel-Cervantes L; Sánchez-Cortés E; Ayala-Sánchez M; Guevara-Moreno ME; García-León LD; Rosas-Cabral A; Esparza MA; González-Llaven J
Bone Marrow Transplant; 2000 Jun; 25(11):1141-6. PubMed ID: 10849526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]